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 Dear Editor,  
In a recent study Negovan et al. assessed the impact of pathological and clinical predisposing factors 
(histological findings, concomitant drug consumption, comorbidities, symptoms, social habits, 
Helicobacter pylori-H. pylori infection) on severe gastro-duodenal lesions in patients on long-term 
low-dose aspirin and proton pump inhibitors (PPI) treatment [1]. They enrolled patients with chronic 
low-dose aspirin and PPI therapy referred for an upper digestive endoscopy between September 2012 
and December 2015. Patients attended esophagogastroduodenoscopy for the following reasons: 
digestive symptoms, anaemia or screening for gastrointestinal bleeding risk (before the initiation of 
combined antithrombotic therapy, before major surgery). Patients with gastro-duodenal surgery, 
varices, active severe bleeding or patients in whom a gastric cancer was discovered were excluded. The 
authors also excluded patients with haematological disorders (leukaemia, lymphoma, aplastic or 
haemolytic anaemia), as well as patients with severe medical conditions (cancer, cardiac, respiratory, 
liver or kidney end-stage disease), autoimmune gastritis, dysplasia. Two biopsy specimens from the 
antrum and two from the corpus were taken for routine histology and were examined by a single 
pathologist. The observed relative frequency of severe gastro-duodenal lesions was 27.4%. There were 
no significant differences between cases (modified Lanza score ≥ 3) and controls regarding H. pylori 
status (21/65 cases vs. 52/172 controls, p=0.875). In the univariate logistic regression model, factors 
associated with severe gastro-duodenal lesions were gender (OR = 1.87, 95% CI: 1.04–3.41), 
assumption of anticoagulants (OR=2.40, 95% CI: 1.26–4.53), gastric atrophy and/or intestinal 
metaplasia (OR = 1.85, 95% CI: 1.04–3.32), congestive heart failure (OR = 2.59, 95% CI: 1.16–6.62), 
anaemia (OR = 3.01, 95% CI: 1.67–5.47) and smoking (OR = 4.29, 95% CI: 1.57–12.32). 
Anticoagulants (p = 0.04) and anaemia (p = 0.02) were risk factors for severe lesions via multivariate 
regression analysis.  
   H. pylori is a slow-growing, micro-aerophilic, Gram-negative bacterium, usually acquired during 
 childhood, whose natural habitat is the luminal surface of the gastric epithelium. At least 50% of the 
world’s human population carries the microorganism, with a prevalence much higher in developing 
countries than in developed countries [2]. H. pylori infection is accepted as the most important cause of 
gastritis and peptic ulcer in humans. Both H. pylori infection and aspirin/non-steroidal anti-
inflammatory drug (NSAID) use are independent risk factors for the development of peptic ulcer and 
associated bleeding; this risk increases when both factors are present [3]. It is well-known that bacterial 
cure alone is not sufficient to prevent ulcer bleeding in NSAID users with high gastrointestinal risks, 
such as a history of ulcer bleeding [4]. Nevertheless, detection and treatment of H. pylori remain two 
key-steps in the strategy for long-term management of these patients.  
   The methods to diagnose H. pylori infection can be classified as invasive or non-invasive, the former 
being based on biopsy specimens obtained at endoscopy. When a patient needs to underwent upper 
gastrointestinal endoscopy, due to alarming symptoms or older age H. pylori infection should be 
detected on biopsies taken in the stomach from two topographical locations, the antrum and the corpus.     
   The authors of the Romanian study [1] searched for H. pylori infection performing two biopsies from 
the antrum and two from the corpus. Thus, this is a correct approach increasing the test’s sensitivity in 
patients currently treated with a PPI drug, but false negative results may still occur if the test is 
performed within seven days of taking PPIs [5]. Stopping PPIs two weeks before testing would allow 
the bacteria to repopulate the stomach and the tests previously negative could once again become 
positive [6]. Regarding the population included by Negovan et al, when possible, PPIs should have 
been stopped two weeks before the upper gastrointestinal endoscopy. When the suspension of the PPI 
was considered risky, in patients with a severe gastro-duodenal lesion and H. pylori negativity at 
histology, the evaluation of antibodies to H. pylori in serum, though marker of exposure and not 
necessarily of “true infection”, it should have been considered, as a confirmatory test. This could be the 
best option considering that other non-invasive tests could be falsely negative in patients with bleeding 
 ulcers or recent use of PPIs.  
   In conclusion, in this study a second test it should have been done in case of H. pylori negativity to 
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